サンプル依頼リスト カート
  • English
  • Korean
表紙：気管支拡張症治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1373371

気管支拡張症治療薬の世界市場-2023年～2030年

Global Bronchiectasis Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
気管支拡張症治療薬の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

気管支拡張症は、炎症や感染によって気管支の壁が厚くなる慢性疾患です。気管支拡張症の患者は、増悪と呼ばれる呼吸困難の再燃を周期的に繰り返します。

気管支拡張症の症状には、息切れを伴う慢性の咳、吐血、胸痛などがあります。増殖や非がん性腫瘍のような気道閉塞も気管支拡張症の原因となります。気管支拡張症の治療に使用される一般的な薬剤には、抗生物質、去痰薬、粘液溶解薬などがあります。

市場力学

気管支拡張症の有病率の増加

気管支拡張症の有病率の増加は、市場成長の重要な促進要因です。気管支拡張症は、慢性閉塞性肺疾患の存在下で発症することが多く、永続的な気管支拡張と重度の気管支炎症によって病理学的に特徴付けられます。

例えば、2022年に発表された国立衛生研究所の報告によると、中国の成人の気管支拡張症の有病率は2.31倍に増加し、10万人当たり75.48人（62.26人、88.69人）から174.45人（137.02人、211.88人）になっています。

さらに、2022年12月に発表されたオーストラリア王立総合診療医学会（Royal Australian College of General Practitioners）の報告書によると、オーストラリア中部の小児における気管支拡張症の推定有病率は10万人当たり1470人であるとしています。

さらに、肺疾患の罹患率の上昇、老年人口の増加、臨床試験の増加などの重要な成長要因が、予測期間中の市場を牽引すると予想されます。

承認薬の不足

気管支拡張症の治療薬が承認されていないこと、規制政策が厳しいこと、研究開発にかかるコストが高いこと、気管支拡張症の診断が不十分であること、代替治療法が好まれることなどが、予測期間における気管支拡張症治療市場の成長を妨げる要因となっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 気管支拡張症の増加
      • 気管支拡張症
    • 抑制要因
      • 承認薬の不足
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 疾患タイプ別

  • CF気管支拡張症
  • 非CF気管支拡張症

第8章 薬剤タイプ別

  • 抗生物質
    • エリスロマイシン
    • クラリスロマイシン
    • ロキシスロマイシン
    • アジスロマイシン
    • アモキシシリン
    • その他
  • 去痰薬
    • 高張食塩水
    • 吸入マンニトール
    • その他
  • 粘液溶解剤
    • ブロムヘキシン
    • N-アセチルシステイン
    • エルドステイン
    • フドステイン
    • その他
  • その他

第9章 投与経路別

  • 経口
  • 非経口
  • 吸入

第10章 流通チャネル別

  • 小売薬局
  • 病院薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Zambon S.p.A.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Pfizer Inc.
  • Merck KGaA
  • Soigner Pharma Pvt Ltd
  • Teva Pharmaceuticals
  • LGM Pharma LLC
  • Texas Pharmaceuticals Pvt. Ltd.
  • Orion Life Science
  • Cepham Life Sciences Inc.
  • AdvaCare Pharma

第14章 付録

目次
Product Code: PH2107

Overview

Bronchiectasis is a chronic condition where the walls of the bronchi are thickened from inflammation and infection. Individuals with bronchiectasis have periodic flare-ups of breathing difficulties called exacerbations.

Symptoms of bronchiectasis include chronic cough with shortness of breath, coughing up blood, and chest pain. The airway blockage like a growth or a noncancerous tumor can also lead to bronchiectasis. Common drugs used in the treatment of bronchiectasis include antibiotics, expectorants, and mucolytics

Market Dynamics

Increasing prevalence of bronchiectasis

The increasing prevalence of bronchiectasis acts as a significant driver for market growth. Bronchiectasis often occurs in the presence of chronic obstructive pulmonary disease and is characterized pathologically by permanent bronchial dilatation and severe bronchial inflammation.

For instance, according to a National Institute of Health report published in 2022, Chinese adults had a 2.31-fold increase in the prevalence of bronchiectasis, going from 75.48 (62.26, 88.69) per 100,000 to 174.45 (137.02, 211.88) per 100,000.

Additionally, according to the Royal Australian College of General Practitioners report published in December 2022, states that the estimated prevalence of bronchiectasis is 1470 per 100,000 in Central Australian children.

Furthermore, significant growth drivers such as the rising incidence of pulmonary diseases, the growing geriatric population, and increasing clinical trials, are expected to drive the market in the forecast period.

The lack of approved drugs

The lack of approved drugs for bronchiectasis, stringent regulatory policies, high costs involved in research and development under-diagnosis of bronchiectasis, and preference for substitute treatment options are some factors hampering the growth of the bronchiectasis treatment market over the forecast period.

Segment Analysis

The global bronchiectasis drugs market is segmented based on disease type, drug type, route of administration, distribution channel, and region.

The antibiotics segment accounted for approximately 52.2% of the market share

Antibiotics are expected to hold the largest market share over the period forecast owing to increasing clinical trials conducted for bronchiectasis with antibiotics. A total of 314 clinical trials were performed till 2023 for the treatment of bronchiectasis with antibiotics.

For instance, according to clinicalTrials.gov, on September 7, 2023, Belfast Health and Social Care Trust in collaboration with Queen's University started a clinical trial of Hypertonic Saline and Carbocisteine in Bronchiectasis. It is currently in phase 3 and the estimated study completion date is September 2024.

Additionally, on September 21, 2023, Insmed Incorporated conducted a clinical trial on the efficacy, safety, and tolerability of Brensocatib in participants with non-cystic fibrosis bronchiectasis. It is currently in phase 3 and the estimated study completion date is March 2024.

Geographical Analysis

North America is expected to hold a significant position in the global bronchiectasis drugs market share

The global bronchiectasis drugs market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of bronchiectasis infections and drug approvals, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Lung Association report published in 2022, The risk of developing bronchiectasis increases with age, and Bronchiectasis affects 350,000 to 500,000 people in the United States. The incidence of bronchiectasis is more common in women than in men.

Additionally, in April 2022, Zambon received a U.S FDA Breakthrough Therapy Designation for colistimethate sodium powder for nebulization solution for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB).

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global bronchiectasis drugs market. The pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new treatment drugs. Therefore, the bronchiectasis drugs market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Zambon S.p.A., Pfizer Inc., Merck KGaA, Soigner Pharma Pvt Ltd, Teva Pharmaceuticals, LGM Pharma LLC, Texas Pharmaceuticals Pvt. Ltd., Orion Life Science, Cepham Life Sciences Inc., AdvaCare Pharma among others.

Key Developments

  • In September 2023, Inogen Inc. acquired Physio-Assist SAS. A technology-enabled airway clearance and mucus management device, Simeox from Physio-Assist, is primarily used to treat bronchiectasis.
  • In December 2022, Life science charity LifeArc partnered with the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) to tackle the respiratory disease bronchiectasis.

Why Purchase the Report?

  • To visualize the global bronchiectasis drugs market segmentation based on disease type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global bronchiectasis drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global bronchiectasis drugs market report would provide approximately 69 tables, 67 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of bronchiectasis
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. The lack of approved drugs
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. CF Bronchiectasis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-CF Bronchiectasis

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Erythromycin
    • 8.2.4. Clarithromycin
    • 8.2.5. Roxithromycin
    • 8.2.6. Azithromycin
    • 8.2.7. Amoxicillin
    • 8.2.8. Others
  • 8.3. Expectorants
    • 8.3.1. Hypertonic Saline
    • 8.3.2. Inhaled Mannitol
    • 8.3.3. Others
  • 8.4. Mucolytics
    • 8.4.1. Bromhexine
    • 8.4.2. N-Acetylcysteine
    • 8.4.3. Erdosteine
    • 8.4.4. Fudosteine
    • 8.4.5. Others
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Inhalation

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Retail Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Zambon S.p.A.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer Inc.
  • 13.3. Merck KGaA
  • 13.4. Soigner Pharma Pvt Ltd
  • 13.5. Teva Pharmaceuticals
  • 13.6. LGM Pharma LLC
  • 13.7. Texas Pharmaceuticals Pvt. Ltd.
  • 13.8. Orion Life Science
  • 13.9. Cepham Life Sciences Inc.
  • 13.10. AdvaCare Pharma

LIST NOT EXHAUSTIVE.

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us